Navigation Links
Cell Toxin Inhibits Survival Protein in Cancer Cells

A chemically-modified version of a mitochondrial toxin long used to control species of invasive fish in lakes has been found to selectively inhibit two "survival proteins in cancer cells.

The research is a first step toward developing a molecularly-targeted drug that could eliminate cellular-level resistance to multiple types of chemotherapy and radiation therapy found in many types of cancers.

scientists at Fred Hutchinson Cancer Research Center report that a modified version of antimycin called 2-Methoxy antimycin is selective in killing cells that have high levels of Bcl-2 and Bcl-xL proteins.

The over expression of these proteins in many types of cancer cells correlates with resistance to chemotherapy and radiation therapy. Cells with normal levels of Bcl-2 or Bcl-xL are resistant to 2-Methoxy antimycin.

David M. Hockenbery, a member of the Hutchinson Centers Clinical Research Division and principal investigator for the study, and colleagues set up screening assays to look for small molecules or compounds that are selectively toxic to cells that over express Bcl-2 proteins.

Higher expression of the target protein made cells more sensitive to the 2-Methoxy antimycin inhibitor. This is called a gain of function mechanism and is counterintuitive to the way most drugs work.

Our compound, 2-Methoxy antimycin, is the only Bcl-2 inhibitor reported with gain of function activity, which provides a therapeutic window between cancer cells with high expression of the proteins versus cells with normal expression, said Hockenbery, who is also a professor of medicine at the University of Washington Medical Center.

This effect was preserved when 2-Methoxy antimycin was used in combination with other agents, and could lead to a targeted molecular therapy to enhance the effectiveness of cancer treatments. Hockenbery said his groups approach illustrated the need to look at how the proteins interact with everything else in the cell. By over expressing this protein, the cell is changed in some interesting ways.

It creates a situation where the cell becomes dependent upon the protein, he said. Cancers can become addicted to certain proteins, so just by over expressing the protein the cell changes so that it cant live without that protein.

The next step in this research is to use the assays his lab developed to cast a wider net to find additional compounds that have similar properties to 2-Methoxy antimycin, Hockenbery said. This strategy has already yielded one additional Bcl-xL inhibitor with "gain of function" activity, reported in the Molecular Cancer Therapeutics paper.

Funding for the study, 2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition, came from the New Technology Development Fund administered by the Hutchinson Center. Additional key investigators in Hockenberys lab included Michael Manion, Ph.D., and Pam Schwartz, Ph.D., and John Fry.

For a pdf of the research paper, please contact Dean Forbes, 206-667-2896 or dforbes@fhcrc.org


'"/>




Related medicine news :

1. Toxins linked with pregnancy loss
2. Toxin connected to Flesh-eating Pneumonia in Kids
3. Vegetables decrease Tobacco Toxins
4. Toxin injections support stroke associated spasticity
5. Indians Stay Away from Coke, Pepsi After Toxin Scare
6. Toxin from the sea to relieve pain
7. Toxin Identified For Alzheimer’s Diseas
8. UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply
9. Gold Nanoparticles Are Good Detectors Biological Toxins
10. Appearance Of Facial Scars Improved By Botulinum Toxin
11. "Beach to Bedside" Study Focuses on Effects of Inhaled Toxins
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... 20, 2017 , ... TwelveStone Health Partners, a premier provider ... equity firm, has invested $3.35 million in the company. , “We have ... offers the smart money, speed to market and accountability we had been looking ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... Fresenius ... specialize in minimally invasive techniques to treat and manage a wide range of vascular ... strategic rebranding initiative. With more than 65 centers represented by more than 40 local ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at ... a host of new options for today’s modern senior. Brazos Towers at Bayou Manor ... lifestyle they love while offering them the services to support that lifestyle both now ...
(Date:6/20/2017)... Midlothian, VA (PRWEB) , ... June 20, 2017 , ... ... latest in three-dimensional imaging technology with the VATECH PaX-i and Anatomage systems. With advanced ... oral cavity so they can place dental implants precisely and restore oral health for ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... -- Less than a month ago, amateur hackers executed an ... hospital networks, in over 150 countries. The ... online extortion attempts ever recorded. With the increasing complexity ... that providers understand where the risks lie, and how ... many other very real cyber threats.  ...
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a brand ... environment to its Iowa location. ... now features an ISO 7 cleanroom—the standard needed to ... with a low level of pollutants. ... nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
Breaking Medicine Technology: